Obigen Pharma

Obigen Pharma EBITDA per Share

The EBITDA per Share of Obigen Pharma (7876.TWO) as of Oct 16, 2026 is -2.30 TWD. In the previous year, EBITDA per Share was -2.00 TWD — a change of 15.00% (lower).

EBITDA per Share

-2.30TWD

YoY

15.00%

Last updated:

EBITDA per Share of Obigen Pharma is 2024 -2.30 TWD. EBITDA per Share of Obigen Pharma was 2023 -2.00 TWD. It decreases by 15.00% lower compared to the previous year.

The Obigen Pharma EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
-1.66 TWD
Jan 1, 2023
-2.00 TWD
Jan 1, 2024
-2.30 TWD
The Obigen Pharma EBITDA per Share history
YEAREBITDA per ShareYoY
-2.30TWD+15.00%
-2.00TWD+20.10%
-1.66TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Obigen Pharma Stock analysis

What does Obigen Pharma do? Obigen Pharma Inc, listed on the Taiwan Stock Exchange under ticker 7876.TWO with ISIN TW0007876005, is a biotechnology company headquartered in Zhubei, Taiwan. The company operates within the Health Care sector and currently employs 57 full-time staff. Obigen Pharma is engaged in the research, development, manufacturing, and commercialization of novel botulinum toxin products. Its primary product, OBI-858, is a type A botulinum toxin formulation currently in phase II clinical trials in Taiwan for the treatment of frown lines in medical aesthetics. The company has established a complete supply chain for OBI-858 within Taiwan, covering research, development, and production. It collaborates with contract research organizations (CROs) to support the advancement of clinical trials for its drug candidates. The company's initial public offering (IPO) is scheduled for November 24, 2025. Obigen Pharma maintains a corporate website at www.obigenpharma.com for further information. Obigen Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Obigen Pharma stock

EBITDA per Share of Obigen Pharma is -2.30 TWD in 2024.

EBITDA per Share of Obigen Pharma changed from -2.00 TWD to -2.30 TWD, representing a 15.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Obigen Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Obigen Pharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Obigen Pharma